Researchers at ITbM, Nagoya University developed a new nickel catalyst with a “Kabuto-like” structure that was found to catalyze the cross-coupling reaction…
Clint Muhlfeld, a research assistant professor in the UM Division of Biological Sciences’ Flathead Lake Biological Station and research ecologist with the USGS…
The slopes of a giant Martian volcano, once covered in glacial ice, may have been home to one of the most recent habitable environments yet found on the Red…
Using your brain – particularly during adolescence – may help brain cells survive and could impact how the brain functions after puberty.
A genetic variant linked to sudden cardiac death leads to protein overproduction in heart cells, Johns Hopkins scientists report. Unlike many known…
After consideration, Aristotle decided that both the egg and the chicken had always existed. That was not the right answer. The new Oregon State University…
The open-access, open-data journal GigaScience (published by BGI and Biomed Central), announces today the publication of an article on the genome sequencing of…
Experiments at the University of Bonn have shown that the expression of MED15, a subunit of the trans-criptional co-regulator Mediator, correlates with the proliferative activity of cells. MED15 is essential for TGF-ß-signaling and control of cholesterol/lipid homeostasis. The protein shows low frequency in androgen-sensitive prostate cancer and lacks expression in benign prostatic tissue.
The co-stimulatory CD40-CD40L dyad is crucial in the development and progression of immune responses and chronic inflammatory diseases, such as atherosclerosis, obesity and multiple sclerosis. However, long-term antibody-mediated inhibition of CD40L or CD40 is not clinically feasible as it results in thromboembolic events and severe immune suppression. More downstream inhibition of the CD40L-CD40 pathway is therefore preferable, especially tumor necrosis factor receptor-associated factors (TRAFs) recruited by CD40. Here we created a set of inhibitors that selectively block CD40-TRAF6 interactions. The rest of the CD40 cascade is left unaffected preventing unwanted immune-suppressive side effects. Therefore, our new inhibitors offer promising candidates as therapeutic agents for the treatment of chronic inflammatory diseases, such as atherosclerosis, obesity and multiple sclerosis.
Scientists at the Sahlgrenska Academy have shown that analysis of the cerebrospinal fluid after concussion can be used to determine the magnitude of brain…
Research student Eva Olofsson has examined the consequences of road traffic injuries in children. One of her studies shows that approximately 30% of children…
The Candidatus Neoehrlichia mikurensis bacterium, known in the medical world by its short name Neoehrlichia, was discovered and described for the first time in…
NRP 60 took a close look at gender equality in Switzerland in 21 research projects. The synthesis of the knowledge gained in the programme is now available….
A new approach to studying microbes in the wild will allow scientists to sequence the genomes of individual species from complex mixtures. It marks a big…
Commercial buildings could cut their heating and cooling electricity use by an average of 57 percent with advanced energy-efficiency controls, according to a…
Calorie restriction, a kind of dieting in which food intake is decreased by a certain percentage, has been touted as way to help people live longer. New…
Feedback
